Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Cancer"
DOI: 10.1002/ijc.32836
Abstract: Bone modifying agents (BMAs) have become a standard treatment to prevent skeletal‐related events (SREs) in bone metastases (BMs). The aim of our study is to determine the clinical value of serum bone resorption markers for… read more here.
Keywords: clinical outcomes; modifying agents; study; serum ... See more keywords
Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review
Sign Up to like & getrecommendations! Published in 2020 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-020-05556-0
Abstract: Purpose Bone-modifying agents (BMAs) for bone metastases are commonly prescribed for many years even though randomized clinical trials are only 1–2 years in duration. A systematic review on the risk-benefit of BMA use for > 2 years in… read more here.
Keywords: bone metastases; systematic review; modifying agents; bone ... See more keywords
Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers
Sign Up to like & getrecommendations! Published in 2022 at "Supportive Care in Cancer"
DOI: 10.1007/s00520-021-06714-8
Abstract: The effect of longer-term use of bone-modifying agent (BMA) on symptomatic skeletal event (SSE) rates in patients with bone metastases remains unclear. This retrospective study of a cohort of patients in a randomized controlled trial… read more here.
Keywords: bone; bone metastases; longer term; bone modifying ... See more keywords
Evaluation of appropriate use of bisphosphonates and denosumab in patients with cancer
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/1078155219842277
Abstract: Background National guidelines recommend screening and treatment for cancer-related bone disease and continued monitoring of bone-modifying agents. It is unclear whether a standardized screening tool is utilized to identify eligible patients and ensure appropriate supportive… read more here.
Keywords: hormone deprivation; bone modifying; cancer; therapy ... See more keywords
Comparative efficacy and safety of bone-modifying agents for the treatment of bone metastases in patients with advanced renal cell carcinoma: A systematic review and meta-analysis.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e16067
Abstract: e16067Background: Bone-modifying agents (BMA) have been well-demonstrated to be effective for preventing and inhibiting skeletal-related events (SRE) in patients with bone metastases of breast or prostate cancer. However, the role of BMA treatment has not… read more here.
Keywords: renal cell; bone metastases; treatment; modifying agents ... See more keywords
Bone modifying agents and skeletal related events in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.e18593
Abstract: e18593 Background: Bone metastases and skeletal related events (SREs) are a common cause of morbidity among patients with metastatic non-small cell lung cancer (mNSCLC). SREs include pathologic bone fractures, spinal cord compression, orthopedic surgery/stabilization, and… read more here.
Keywords: bone modifying; bone metastases; histology; bma ... See more keywords
Use of bone modifying agents in patients with metastatic castrate-sensitive prostate cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.6_suppl.68
Abstract: 68Background: Bone modifying agents (BMAs) do not prevent skeletal related events (SREs) among patients with metastatic, castration-sensitive prostate cancer (mCSPC). Within this population, BMAs a... read more here.
Keywords: modifying agents; sensitive prostate; bone modifying; patients metastatic ... See more keywords
Use of bone-modifying agents among breast cancer patients with bone metastasis: evidence from oncology practices in the US
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Epidemiology"
DOI: 10.2147/clep.s175063
Abstract: Purpose Bone-modifying agents (BMAs) are recommended for women with bone metastasis from breast cancer to prevent skeletal-related events. We examined the usage patterns and identified the factors associated with the use of BMAs (denosumab and… read more here.
Keywords: breast cancer; bone; bone modifying; bone metastasis ... See more keywords
Medication-related osteonecrosis of the jaw: knowledge and perceptions of medical professionals on the usage of bone modifying agents and dental referrals.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medicine and life"
DOI: 10.25122/jml-2021-0085
Abstract: Bone modifying agents (BMA) like bisphosphonates, antiangiogenic, and antiresorptive agents are widely used to manage bone diseases and cancer. Medication-related osteonecrosis of the jaw (MRONJ) is a potentially serious complication seen in patients on BMA… read more here.
Keywords: modifying agents; bone modifying; medication related; knowledge ... See more keywords